Eyepoint Pharmaceuticals (NASDAQ:EYPT) Announces Earnings Results

Eyepoint Pharmaceuticals (NASDAQ:EYPT) posted its earnings results on Thursday. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.14), FiscalAI reports. The company had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.23 million. Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%.

Here are the key takeaways from Eyepoint Pharmaceuticals’ conference call:

• Both Phase III wet AMD trials missed their primary endpoint in the full analysis population. EyePoint highlighted DURAVYU’s biological activity, reduced treatment burden, and safety, but is discontinuing the wet AMD program while it reviews whether any patient subgroup could support a future path.
• EyePoint ended September with about $118 million in cash and expects to fund operations into late Q3 2027, while COMO and CAPRI results are expected in early Q4 2027. Management says it is evaluating additional cost reductions, financing, and business-development options to preserve runway and reach the readouts.
• EyePoint is concentrating its clinical efforts on DME, citing the disease’s distinct biology and Phase II VERONA results, including vision improvement and fewer supplemental injections with DURAVYU. The company expects simultaneous top-line results from the two Phase III trials, which enrolled more than 550 patients, in early Q4 2027; efficacy in these pivotal studies remains unproven.
• After the wet AMD results, EyePoint amended DME rescue-injection criteria so patients may receive supplemental treatment after a greater-than-five-letter BCVA decline from baseline alongside a CST increase of at least 50 microns. The company says the change is intended to help preserve vision and protect the trials’ non-inferiority objective; it is not planning a futility analysis.
• EyePoint plans to reduce its workforce by about 53% and says the move will generate approximately $30 million in annualized savings once fully implemented, aligning spending with the DME program.

Eyepoint Pharmaceuticals Stock Down 7.7%

EYPT traded down $0.03 during trading on Thursday, reaching $0.33. The stock had a trading volume of 4,003,271 shares, compared to its average volume of 3,681,834. The stock has a 50 day moving average of $2.50 and a two-hundred day moving average of $10.40. The firm has a market capitalization of $28.36 million, a price-to-earnings ratio of -0.09 and a beta of 1.84. Eyepoint Pharmaceuticals has a 1-year low of $0.31 and a 1-year high of $19.11.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on EYPT shares. Stifel Nicolaus assumed coverage on Eyepoint Pharmaceuticals in a research report on Thursday, July 16th. They issued a “buy” rating and a $40.00 target price on the stock. Wall Street Zen raised shares of Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, September 27th. Citigroup reduced their price target on shares of Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating for the company in a report on Tuesday, August 18th. Jefferies Financial Group lowered shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.00 price target for the company. in a research report on Monday, October 19th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Eyepoint Pharmaceuticals in a report on Tuesday, October 20th. Two investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $21.85.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals is a biopharmaceutical company focused on developing treatments for serious eye diseases. Its drug-delivery technology is designed to provide sustained release of medication in the eye, with the goal of reducing the need for frequent injections or other repeated treatments. The company’s pipeline includes DURAVYU, an investigational sustained-release treatment being studied for retinal conditions including wet age-related macular degeneration and diabetic retinopathy. EyePoint previously developed and marketed ophthalmic products including YUTIQ and DEXYCU, and sold those commercial assets to Alimera Sciences in 2023.